Dr. Baltimore Says It's Time to Revive AIDS Vaccine Ideas

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines, Nobel laureate David Baltimore, PhD, told the Advisory Committee to the Director of the National Institutes of Health.

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines,Nobel laureate David Baltimore, PhD, told the Advisory Committee to theDirector of the National Institutes of Health.

Dr. Baltimore, currently at the Massachusetts Institute of Technologyand president-elect of the California Institute of Technology, chairs anadvisory committee named by NIH director Harold Varmus, MD, to devise acomprehensive national research program to develop an effective AIDS vaccine.Looking at the candidate AIDS vaccines tested so far, Dr. Baltimore expressedhis concern that none of them may be able to effectively prevent the disease.

The growing understanding of how the human immunodeficiency virus changesand functions has led him to conclude that scientists need to reconsidera variety of vaccine approaches discarded earlier, he said. These includekilled viruses, virus-like particles, protein-based vaccines, naked DNA,and live, attenuated vaccines.

Because a live vaccine would involve actually infecting people, albeitwith a crippled virus, "that concept is appropriately worrisome,"Dr. Baltimore acknowledged. Nonetheless, that approach could be the mosteffective.

"What the committee is doing is trying to suggest new scientificinitiatives," he said. "What we'd most like to do is get newvaccine concepts under testing." However, he emphasized that an AIDSvaccine will take years to perfect: "It is intrinsic to the developmentthat it takes a long time."

Dr. Baltimore said the AIDS vaccine committee has held a series of regionalworkshops intended to generate new ideas and bring new minds into the effort."We would like to encourage people who have not worked on HIV to comeinto the field," he said.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content